Core Viewpoint - The company InSilico Medicine officially listed on the Hong Kong Stock Exchange on December 30, marking a significant milestone in its growth and development within the biopharmaceutical sector [1]. Group 1: Company Overview - InSilico Medicine has established a team in Pudong since 2019, which has grown to nearly 200 members [1]. - The company plans to further deepen its business layout in Pudong and enhance team building focused on high-quality talent [1]. Group 2: Industry Context - Pudong has a vibrant biopharmaceutical ecosystem, featuring a dense concentration of related enterprises, research institutions, and professional talent [1]. - The ecosystem covers the entire chain from early exploration and clinical research to industrialization [1].
浦东创投集团战略投资企业英矽智能登陆港交所